Induction of distinct neuroinflammatory markers and gut dysbiosis by differential pyridostigmine bromide dosing in a chronic mouse model of GWI showing persistent exercise fatigue and cognitive impairment

Life Sci. 2022 Jan 1:288:120153. doi: 10.1016/j.lfs.2021.120153. Epub 2021 Nov 18.

Abstract

Aims: To characterize neuroinflammatory and gut dysbiosis signatures that accompany exaggerated exercise fatigue and cognitive/mood deficits in a mouse model of Gulf War Illness (GWI).

Methods: Adult male C57Bl/6N mice were exposed for 28 d (5 d/wk) to pyridostigmine bromide (P.O.) at 6.5 mg/kg/d, b.i.d. (GW1) or 8.7 mg/kg/d, q.d. (GW2); topical permethrin (1.3 mg/kg), topical N,N-diethyl-meta-toluamide (33%) and restraint stress (5 min). Animals were phenotypically evaluated as described in an accompanying article [124] and sacrificed at 6.6 months post-treatment (PT) to allow measurement of brain neuroinflammation/neuropathic pain gene expression, hippocampal glial fibrillary acidic protein, brain Interleukin-6, gut dysbiosis and serum endotoxin.

Key findings: Compared to GW1, GW2 showed a more intense neuroinflammatory transcriptional signature relative to sham stress controls. Interleukin-6 was elevated in GW2 and astrogliosis in hippocampal CA1 was seen in both GW groups. Beta-diversity PCoA using weighted Unifrac revealed that gut microbial communities changed after exposure to GW2 at PT188. Both GW1 and GW2 displayed systemic endotoxemia, suggesting a gut-brain mechanism underlies the neuropathological signatures. Using germ-free mice, probiotic supplementation with Lactobacillus reuteri produced less gut permeability than microbiota transplantation using GW2 feces.

Significance: Our findings demonstrate that GW agents dose-dependently induce differential neuropathology and gut dysbiosis associated with cognitive, exercise fatigue and mood GWI phenotypes. Establishment of a comprehensive animal model that recapitulates multiple GWI symptom domains and neuroinflammation has significant implications for uncovering pathophysiology, improving diagnosis and treatment for GWI.

Keywords: Central nervous system; Endotoxemia; Gut microbiome; Gut-brain axis; Interleukins; Intestinal permeability; Probiotic; Toxic wounds.

MeSH terms

  • Animals
  • Biomarkers / analysis
  • Cholinesterase Inhibitors / administration & dosage
  • Cholinesterase Inhibitors / toxicity
  • Cognitive Dysfunction / etiology
  • Cognitive Dysfunction / metabolism
  • Cognitive Dysfunction / pathology*
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Dysbiosis / etiology
  • Dysbiosis / metabolism
  • Dysbiosis / pathology*
  • Endotoxemia / etiology
  • Endotoxemia / metabolism
  • Endotoxemia / pathology
  • Fatigue / etiology
  • Fatigue / metabolism
  • Fatigue / pathology*
  • Gastrointestinal Microbiome*
  • Gene Expression Profiling
  • Gene Expression Regulation / drug effects
  • Gliosis / etiology
  • Gliosis / metabolism
  • Gliosis / pathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neuralgia / etiology
  • Neuralgia / metabolism
  • Neuralgia / pathology
  • Neuroinflammatory Diseases / etiology
  • Neuroinflammatory Diseases / metabolism
  • Neuroinflammatory Diseases / pathology*
  • Persian Gulf Syndrome / drug therapy*
  • Physical Conditioning, Animal*
  • Pyridostigmine Bromide / administration & dosage
  • Pyridostigmine Bromide / toxicity*

Substances

  • Biomarkers
  • Cholinesterase Inhibitors
  • Pyridostigmine Bromide